Of note, E6 and E7 oncoproteins could not be therapeutically targeted so far, making it essential to explore druggable targets for HPV+ HNSCC, in which mTOR inhibition provides suitable therapeutic options [31]. This evidence concerns the gene MTOR and head and neck squamous cell carcinoma.